Courtenay C. Brinckerhoff

Courtenay C. Brinckerhoff

Foley & Lardner LLP

Contact  |  View Bio  |  RSS

Latest Posts › Obviousness

Share:

Patent Reform: The Leahy Patent Transparency and Improvements Act

Now that the Goodlatte Innovation Act has passed the House, its provisions likely will be reconciled with the Patent Transparency and Improvements Act (S. 1720) that was introduced in the Senate by Senator Leahy (D-Vt.) on...more

12/17/2013 - Disclosure Requirements Double Derivative Claims First-to-File Innovation Act Inventors Obviousness Patent Reform Patents

Federal Circuit Invalidates Galderma Differin Patents

In Galderma Laboratories v. Tolmar, Inc., the Federal Circuit reversed the district court’s findings that the Orange Book-listed patents for Galderma’s Differin® 0.3% gel product were not invalid as obvious. In so doing, the...more

12/12/2013 - ANDA Obviousness Patents Pharmaceutical Prior Art

Federal Circuit Reverses Board Rejections That Strayed From Claim Construction

In the non-precedential decision in In re Eaton, the Federal Circuit reversed the USPTO Board decision affirming rejections of anticipation and obviousness. The court found that the Board decision strayed from its own claim...more

12/2/2013 - Claim Construction Obviousness Patent Litigation Patents USPTO

Goodlatte Proposes an Obviousness Type Double Patenting Statute

One of the provisions of the Innovation Act introduced by Congressman Goodlatte (R-VA) on October 23, 2014, purports to codify the doctrine of obviousness-type double patenting for applications and patents examined under the...more

11/6/2013 - First-to-File First-to-Invent Innovation Act Obviousness Patent Reform Patents Prior Art

Federal Circuit Vacates PTAB Decision Invalidating Rambus Patent

In Rambus, Inc. v. Rea, the Federal Circuit found several legal and procedural errors in the decision of the USPTO Patent Trial and Appeal Board (PTAB) that invalidated certain claims of the Rambus patent as obvious. While...more

10/4/2013 - Evidence Obviousness Patent Trial and Appeal Board Patents USPTO

Federal Circuit Finds Taclonex Patent Not Obvious, Reverses USPTO Decision

In Leo Pharmaceutical Products, Lt. v. Rae, the Federal Circuit issued a rare decision reversing an obviousness determination by the USPTO Patent Trial and Appeal Board (PTAB)....more

8/21/2013 - Obviousness Patents Pharmaceutical Pharmaceutical Patents Prior Art USPTO

Federal Circuit Invalidates Prandin Patent Claim as Obvious

In its third look at the Novo Nordisk A/S patent related to Prandin®, in Novo Nordisk A/S v. Caraco Pharmaceutical Laboratories Ltd., the Federal Circuit affirmed the district court’s finding that claim 4 of U.S. Patent No....more

6/27/2013 - ANDA Obviousness Patents Pharmaceutical Prescription Drugs USPTO

Federal Circuit Upholds One Claim Covering Combigan

In Allergan, Inc. v. Sandoz, Inc., the Federal Circuit reversed the district court in part, finding that Allergan’s composition claims and most of its method claims are invalid as obvious, but upholding one method claim...more

5/8/2013 - Allergan Inc Combination Products Hatch-Waxman Obviousness Patents

Federal Circuit Finds Obviousness-Type Double Patenting Without Common Ownership

Obviousness-type double patenting usually arises between commonly-owned patents or patent applications. While the USPTO has interpreted the judicially-created doctrine as pertaining when there is common or overlapping...more

3/13/2013 - Common Ownership Obviousness Patent Applications Patents

Federal Circuit Holds the Reexamination Door Open in In Re Baxter

When the Federal Circuit denied the Request for Panel Rehearing and Rehearing en banc in In re Baxter, the court let stand its two decisions that affirmed conflicting rulings on the validity of the same patent....more

11/30/2012 - Inter Partes Review Proceedings Obviousness Patents Split of Authority

10 Results
|
View per page
Page: of 1